There is an ongoing discussion about the value of adenylyl cyclase 5 (AC5) as drug target for treatment of heart failure. This letter discusses statistical, pharmacokinetic, and pharmacodynamic reasons why the recently proposed cardioprotective effects of vidarabine cannot be readily attributed to AC5 inhibition.
- Received April 7, 2016.
- Accepted May 25, 2016.
- Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics